Antigen Preparation
"A synthetic peptides from N-terminus of human STK17b. This sequence is identical among human, rat and mouse."
Background
"STK17b, a serine/threonine kinase 17b, is also called DRAK2. DRAK2 serves as a TGF-β1-inducible antagonist of TGF-β signaling. TGF-β1 stimulation rapidly induces DRAK2 expression and enhances endogenous interaction of the type I TGF-β receptor with DRAK2, thereby blocking R-Smads recruitment. Depletion of DRAK2 expression markedly augmented the intensity and the extent of TGF-β1 responses. Furthermore, a high level of DRAK2 expression was observed in basal-like and HER2-enriched breast tumors and cell lines, and depletion of DRAK2 expression suppressed the tumorigenic ability of breast cancer cells. DRAK2 is an intrinsic intracellular antagonist participating in the negative feedback loop to control TGF-β1 responses, and aberrant expression of DRAK2 increases tumorigenic potential, in part, through the inhibition of TGF-β1 tumor suppressor activity."
Applications/Suggested Working Dilutions
|
|
|
Immunoprecipitation
2-5 µg/ml
|
|
Flow cytometry
Not tested
|